Abstract: A method of estimating greenhouse gas emission, performed by a processing device, includes: obtaining at least one time period of a number of working stations for a target manufacturing process of a product; obtaining a number of first power consumption data of the target manufacturing process, wherein the first power consumption data correspond to the working stations respectively; calculating a number of second power consumption data based on the at least one time period and the first power consumption data; searching for a number of target coefficients corresponding to the plurality of working stations respectively in coefficient database based on the target manufacturing process; and calculating greenhouse gas emission data of the target manufacturing process based on the second power consumption data and the target coefficients.

Abstract: A respiratory function testing system includes an air transforming device, a sound reception device and an operation device. The air transforming device is configured to collect exhaled and/or inhaled air for a predetermined period and generate a wide frequency range sound signal according to the collected respired air. The wide frequency range sound signal at least contains an ultrasonic signal. The sound reception device is configured to receive and record the wide frequency range sound signal as an audio file. The operation device is in communication with the sound reception device and is configured to receive and compute the audio file to generate a respiratory function parameter. Besides, the recorded wide frequency range sound signal may be converted into a spectrogram for further applications, and the computation of the audio file can be replaced by analyzing the spectrogram. A respiratory function testing method corresponding to the respiratory function testing system is also provided.

Abstract: The invention discloses that a kefir peptide with an amino acid sequence of SEQ ID No: 2 or a fermentation product comprising the kefir peptide has an antidepressant activity, which means that by administering an effective amount of the kefir peptide or a composition comprising an effective amount of the kefir peptide to an individual with depressive behaviors is capable of effectively improving or alleviating the individual's depressive behaviors. Since the kefir peptide disclosed in the invention is not a chemical compound, the kefir peptide will not have side effects on the human body even taking it on a long-term basis.

Abstract: The invention discloses that a kefir peptide with an amino acid sequence of SEQ ID No: 2 or a fermentation product comprising the kefir peptide has an antidepressant activity, which means that by administering an effective amount of the kefir peptide or a composition comprising an effective amount of the kefir peptide to an individual with depressive behaviors is capable of effectively improving or alleviating the individual's depressive behaviors. Since the kefir peptide disclosed in the invention is not a chemical compound, the kefir peptide will not have side effects on the human body even taking it on a long-term basis.

Abstract: The present invention discloses a method for treating or/and preventing calcium deficiency-related diseases, which comprises administering a composition containing an effective amount of a peptide to a subject, wherein the peptide has an amino acid sequence as shown in SEQ ID NO. 3. The calcium ions are allowed to bind to the peptide and enter the cells of the patient, to achieve the effect of treating or/and preventing calcium deficiency-related diseases.

Abstract: A seawater battery includes an anode and a cathode corresponding to the anode. The cathode cooperates with the anode to produce a current and includes a metal substrate and a mixture coating layer. The mixture coating layer covered on the metal substrate includes a conductive polymer material and a plurality of carbon nanotubes mixed with the conductive polymer material.

Abstract: The present invention discloses a method for treating or/and preventing calcium deficiency-related diseases, which comprises administering a composition containing an effective amount of a peptide to a subject, wherein the peptide has an amino acid sequence as shown in SEQ ID NO. 3. The calcium ions are allowed to bind to the peptide and enter the cells of the patient, to achieve the effect of treating or/and preventing calcium deficiency-related diseases.

Abstract: A seawater battery includes an anode and a cathode corresponding to the anode. The cathode cooperates with the anode to produce a current and includes a metal substrate and a mixture coating layer. The mixture coating layer covered on the metal substrate includes a conductive polymer material and a plurality of carbon nanotubes mixed with the conductive polymer material.

Abstract: The present invention discloses a novel milk-fermented product comprising a group of peptides. The peptides are composed from no. 1 to no. 7 of the figure that is selected from the group consisting of FIG. 11 to FIG. 18. And the novel milk-fermented product is used for suppressing the reduction of bone mineral density. Therefore, the novel milk-fermented product could be a component of foods, nutrient supplement or medicine for treating or preventing osteoporosis.

Abstract: The present invention discloses a novel milk-fermented product comprising a group of peptides. The peptides are composed from no. 1 to no. 7 of the figure that is selected from the group consisting of FIG. 11 to FIG. 18. And the novel milk-fermented product is used for suppressing the reduction of bone mineral density. Therefore, the novel milk-fermented product could be a component of foods, nutrient supplement or medicine for treating or preventing osteoporosis.

Abstract: The present invention discloses a novel milk-fermented product comprising a group of peptides. The peptides are composed from no. 1 to no. 7 of the figure that is selected from the group consisting of FIG. 11 to FIG. 18. And the novel milk-fermented product is used for suppressing the reduction of bone mineral density. Therefore, the novel milk-fermented product could be a component of foods, nutrient supplement or medicine for treating or preventing osteoporosis.

Abstract: The invention provides a new type of a capsid protein VP1 of human enterovirus 71, named as MEL701-VP1 and functional/structural variants thereof, which is used for protection against enterovirus. The transgenic animal producing the protein, the composition comprising the protein and the method for production thereof are also provided.

Abstract: The invention provides a new type of a capsid protein VP1 of human enterovirus 71, named as MEL701-VP1 and functional/structural variants thereof, which is used for protection against enterovirus. The transgenic animal producing the protein, the composition comprising the protein and the method for production thereof are also provided.

Abstract: The invention provides a new type of a capsid protein VP1 of human enterovirus 71, named as MEL701-VP1 and functional/structural variants thereof, which is used for protection against enterovirus. The transgenic animal producing the protein, the composition comprising the protein and the method for production thereof are also provided.

Abstract: The invention provides a transgenic animal producing low-lactose milk, which is transformed with a gene encoding an extracellular lactase-hydrolyzing enzyme cloned from a human small intestinal cDNA library. The invention also provides a new extracellular lactase-phlorizin hydrolase (ecLPH) gene that can express human lactase-hydrolyzing enzyme in the mammary gland of animals. The invention can be used in the production of low-lactose milk.

Abstract: An electrostatic discharge protection circuit includes: an electrostatic protection device coupled between a first reference voltage terminal and a signal pad for protecting a circuit coupled to the signal pad; a bipolar junction transistor including an emitter terminal coupled to the signal pad, a collector terminal coupled to a second reference voltage terminal, and a base terminal coupled to the first reference voltage terminal, wherein the bipolar junction transistor is a parasitic bipolar junction transistor of the electrostatic protection device; and a clamping circuit coupled to the bipolar junction transistor for clamping a conductivity of the bipolar junction transistor according to a signal received at the signal pad.

Abstract: The present invention provides a novel antihypertensive peptide. Also provided are pharmaceutical and food compositions containing the antihypertensive peptide for treating hypertension or cardiovascular disease.

Abstract: The invention provides a new type of a capsid protein VP1 of human enterovirus 71, named as MEL701-VP1 and functional/structural variants thereof, which is used for protection against enterovirus. The transgenic animal producing the protein, the composition comprising the protein and the method for production thereof are also provided.

Abstract: The present invention provides a novel antihypertensive peptide. Also provided are pharmaceutical and food compositions containing the antihypertensive peptide for treating hypertension or cardiovascular disease.

Abstract: The invention provides a transgenic animal producing low-lactose milk, which is transformed with a gene encoding an extracellular lactase-hydrolyzing enzyme cloned from a human small intestinal cDNA library. The invention also provides a new extracellular lactase-phlorizin hydrolase (ecLPH) gene that can express human lactase-hydrolyzing enzyme in the mammary gland of animals. The invention can be used in the production of low-lactose milk.